Keebeck Wealth Management’s Altimmune ALT Stock Holding History

Keebeck Wealth Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20,000	Closed	-$226K	–	218
2021 Q3	$226K	Hold	20,000	–	–	0.04%	195
2021 Q2	$197K	Hold	20,000	–	–	0.03%	233
2021 Q1	$283K	Hold	20,000	–	–	0.04%	204
2020 Q4	$226K	Hold	20,000	–	–	0.04%	196
2020 Q3	$264K	Hold	20,000	–	–	0.05%	164
2020 Q2	$214K	Buy	+20,000	New	+$110K	0.07%	154

Other funds holding ALT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Keebeck Wealth Management's ALT Position: Q4 2021 in Review

Keebeck Wealth Management sold out of Altimmune (ALT) in Q4 2021, closing a stake of 20,000 shares — an estimated $226K sold.

Keebeck Wealth Management first reported a position in ALT in Q2 2020 and held it in 6 quarters. The position peaked at $283K in Q1 2021. 102 funds tracked by Wall St. Rank hold ALT as of Q4 2021.

Keebeck Wealth Management reported no remaining Altimmune position as of Q4 2021 after selling out during the quarter.
Keebeck Wealth Management sold 20,000 Altimmune shares in Q4 2021, an estimated $226K.
Keebeck Wealth Management first reported a position in Altimmune in Q2 2020 and held it in 6 quarters.
Keebeck Wealth Management's Altimmune position peaked at $283K in Q1 2021.
102 funds tracked by Wall St. Rank held Altimmune as of Q4 2021.

Based on Keebeck Wealth Management's 13F filing for Q4 2021, filed 14 Feb 2022.